Skip to main content

Table 1 Patients baseline characteristics

From: The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment

Parameters

ARMS

   
 

Control (n=75)

Nevirapine (n=128)

Efavirenz (n=66)

P value

Sex (female) %

65

79.5

52.3

 

Median age in years

38 (19–64)

42 (21–67)

43 (39–66)

0.015

Temperature mean, SD ± OC

38.1 ± 0.8

37.8 ± 1.3

38.3± 0.9

0.485

Median weight (IQR)

56 (41–92)

55 (41–78)

58 (36–84)

0.953

Median (range) parasite density/μL

1280 (560–4040)

4040 (600–261520)

3440 (480–126960)

0.564

Haemaglobin (g/dL) median (IQR)

13.9 (12.2-15.2)

12.1 (11.2-13.5)

12.3 (10.2-13.6)

0.036

CD4+ count (x106/L) median (IQR)

402 (66–964)

354 (19–1781)

298 (9–694)

0.002